FGL
Also known as: FG Loop Peptide, NCAM Mimetic
NCAM-Derived Peptide | Synaptic Plasticity & Neuroprotection
Overview
FGL is a synthetic peptide derived from the second fibronectin type III module of neural cell adhesion molecule (NCAM). It mimics the interaction between NCAM and fibroblast growth factor receptor 1 (FGFR1), activating downstream signaling cascades that promote synaptic plasticity, neurogenesis, and neuroprotection. Research has primarily been conducted in animal models, where FGL has shown promise for cognitive enhancement, stroke recovery, and neurodegenerative disease models.
Key benefits
- Activates FGFR1 to promote synaptic plasticity
- Stimulates hippocampal neurogenesis
- Provides neuroprotection against excitotoxic and ischemic injury
- Enhances long-term potentiation (LTP) in preclinical models
- Potential cognitive enhancement via NCAM-mimetic signaling
Mechanism of action
FGL binds to and activates FGFR1, triggering receptor autophosphorylation and downstream signaling through the MAPK/ERK and PI3K/Akt pathways. This activation promotes long-term potentiation (LTP), enhances synaptic plasticity, stimulates neurogenesis in the hippocampus, and provides neuroprotective effects against excitotoxicity and oxidative stress.
Molecular data
- Type
- Synthetic peptide derived from the second fibronectin type III module of NCAM
- Half-life
- Not well characterized
Indications
What the research community uses this compound for, with self-reported effectiveness.
Cognitive
Neuroprotection
Neuroplasticity
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 100-200mcg | 1x daily | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Injection site reactions (redness, mild swelling, irritation)
Contraindications
- Pregnancy or breastfeeding
- Known peptide or NCAM-related compound allergies
- Very limited human safety data -- use with caution under medical supervision
Monitoring
- Start at the low end of the dose range (100mcg) to assess tolerance
- Monitor injection sites for reactions
- Human pharmacokinetic and safety data is extremely limited -- proceed conservatively
References
Primary literature and clinical-trial data informing this entry.